On April 28, 2021, Pfizer Inc. announced that it has acquired Amplyx Pharmaceuticals, Inc., a privately held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections. In addition to Fosmanogepix, with this acquisition, Pfizer has secured ownership of Amplyx's early-stage pipeline that includes potential antiviral (MAU868) and antifungal (APX2039) therapies. Wilson Sonsini Goodrich & Rosati advised Amplyx on IP matters related to the transaction.

The acquisition of Amplyx follows an initial equity investment by Pfizer in December 2019 as part of Amplyx’s Series C financing. At that time, Pfizer joined a world-class group of biotechnology investors that included 3×5 Partners, Adage Capital Management, Arix Bioscience, BioMed Ventures, Lundbeckfonden Ventures, New Enterprise Associates, Pappas Capital, RiverVest Venture Partners, and Sofinnova Investments.

Financial terms of this acquisition were not disclosed.

A Wilson Sonsini Goodrich & Rosati team that was led by Val Zunic and included Tyler Baguley and Mike Hostetler advised Amplyx on IP matters related to the acquisition.

For more information, please see Pfizer’s press release.